Thereby, we are able to recapitulate our in vitro results by reducing serum PSA and expression levels of target proteins in the xenograft tumors.
INTRODUCTION
While highly effective and in most cases curative treatment options exist for clinically localized prostate cancer (PCa), treatment options for recurrent and metastatic PCa are limited and mostly palliative (1, 2) . Androgen deprivation therapy (ADT) remains the most effective therapy for men with advanced disease, and while up to 80% show initial response, castrate resistant prostate cancer (CRPC) progression almost invariably occurs within 24 months. Androgen ablation induces apoptosis in subpopulations of PCa cells, but despite high initial response rates, remissions are temporary because surviving tumor cells usually recur with an AI phenotype (3) (4) (5) . CRPC progression is a complex process by which cells acquire the ability to both survive and proliferate in the absence of androgens and involves variable combinations of clonal selection, adaptive upregulation of anti-apoptotic genes and alternative growth factor pathways (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Molecular targeting at this stage seems to be a promising approach (19) .
The Signal Transducer and Activator of Transcription (Stat)-5 signaling cascade is known to play a pivotal role in the progression of PCa (20) (21) (22) (23) . Stat5 expression in human PCa tissue correlates with high histological grades of PCa and predicts early disease recurrence after initial treatment with radical prostatectomy (24, 25) . Furthermore, ADT increases the frequency of Stat5-expression in human PCa (26) . Stat5a is involved in the maintenance of prostate epithelial structures while Stat5b mediates cell growth (21, 27) . In vitro, Stat5 promotes PCa progression by increasing the expression levels of Cyclin-D1 and Bcl-xL (23) and transcriptional activity of AR (26) . This finding is of major interest as AR signaling pathway remains active in CRPC despite low levels of circulatory androgens after ADT (28, 29) . The functional importance of Stat5 in PCa in vivo has been demonstrated in Stat5b-negative C2H cells which were unable to form tumors (21) . Moreover, tumor growth in vivo was inhibited in CWR22Rv cells infected with adenovirus expressing dominant negative Stat5a/b (23) . The objectives of the current study 
Treatment of prostate cancer cells with oligonucleotides
A 2'-methoxyethyl-modified phosphorotiate ASO for the coding region of Stat5a and Stat5b (ISIS 424751) was synthesized by ISIS Pharmaceuticals (Carlsbad, CA). The sequence of the Stat5-ASO is 5' TCCACGCGGTACTGCTGCAG-3'. The control oligonucoleotide (ScrB) used is designed not to match any mRNA in human or mouse transcriptomes and has the sequence 5'-CCTTCCCTGAAGGTTCCTCC-3'. C4-2 and DU145 cells were plated at the density of Cell growth was assessed using crystal violet assay, as described previously (30) . Cells were plated in 12-well plates and treated with ASO as described above. Crystal violet staining was carried out for dose-dependent treatment 3 days post transfection and for time-course 1, 2 and 3 days post transfection. The absorbance was determined with a microculture plate reader (Becton Dickinson Labware) at 562nm. Cell survival after ASO treatment was calculated as the percentage of the absorbance in vehicle-treated cells.
Apoptosis assays
Detection and quantification of apoptotic cells were done by flow cytometric analysis. Cells were plated in 10 cm 2 dishes and transfected as described above. 2 days later cells were trypsinized and fixed in 70% ethanol over night at 4 C, then incubated with 1 µg/mL RNase (Sigma) for 30min at 37C before stained with 5µg/mL propidium iodide (Sigma) for 30min at room temperature. The stained cells were analyzed for relative DNA content on a dual laser flow cytometer (Beckman Coulter Epics Elite; Beckman, Inc.). Each assay was done in triplicate.
Caspase-3 activity was assessed two days after treatment using the kit CaspACE Assay System, Fluorometric (Promega, Madison, WI, USA). Aliquots of 50µg of total cell lysate were incubated with caspase-3 substrate AC-DEVD-AMC at room temperature for 16 h. The caspase activity was quantified in a fluorometer with excitetion at 360nm and emission at 460nm.
Western blot analysis
Cell population was harvested three days post transfection in RIPA buffer (50nM Tris, pH 7. specific bands their densiometric quantification was done using the ODYSSEY IR imaging system (Li-COR Biosciences).
Luciferase assay
LNCaP and C4-2 cells were plated on 12 well plates and transfected with Stat5-ASO or ScrB together with PSA-Luciferase-Plasmid (6.1) using lipofectin (1.5 uL per well; Invitrogen Life Technologies, Inc.). The total amount of PSA-plasmid DNA used was normalized to 0.5 µg per well by the addition of a control plasmid. Cells were transfected at different concentrations for two consecutive days. Media were replaced by charcoal stripped serum (CSS; Thermo scientific) + 0.1nm R1881 (PerkinElmer) 24h after last transfection for another 24h. Luciferase activities measured using the Dual-Luciferase Reporter Assay System (Promega) with the aid of a microplate luminometer (EG&G Berthold). All experiments were carried out in triplicate wells and repeated two times.
Immunofluorescence
LNCaP and C4-2 cells were grown on coverslips in 12-well plates. For Stat5 knockdown, cells were transfected with 30nM Stat5 ASO as described above. 2 days after second transfection, cells were treated +R1881 for 15min and thereafter fixed in ice-cold methanol completed with 3% acetone for 10min at -20C. Cell were then washed thrice with PBS and incubated with 0.2% Triton/PBS for 10 min, followed by washing and 30 min blocking in 3% nonfat milk before AR antibody addition overnight (1:250). Antigens were visualized using anti-rabbit antibodies coupled to FITC or rhodamine (1:500; 30 min). Photomicrographs were taken at 40x magnification using Zeiss Axioplan II fluorescence microscope, followed by analysis with imaging software (Northern Eclipse, Empix Imaging, Inc.). 
Protein stability and degradation
To assess the effect of Stat5-ASO on protein stability, cyclohexamide (CHX; Calbiochem / chemical structure see supplemental Figure 1A ) was added at 10µg/ml to the culture media of 
Statistical analysis
All results were expressed as the average + SE, and the significance of differences were measured by Student's t-test or Fisher's exact test (Medcalc software). P < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered significant. 
RESULTS

Stat5 expression is associated with high Gleason grade, ADT and castration-resistant disease
To characterize levels of Stat5 expression in primary PCa with progression to CRPC, we analyzed staining patterns in human prostate cancer tissues before and after ADT. Figure 1A illustrates that Stat5 expression is low in untreated tumors but increases after androgen ablation.
Stat5 expression is predominantly nuclear with weaker cytoplasmic expression in the PCa cells.
Stat5 expression is significantly more frequent (*, p<0.05) in high Gleason grade compared to low Gleason grade (Fig. 1B left) . Furthermore, Stat5 expression increased in short-(87.5%, *p<0.05) and long-(94.7%, ***p<0.001)) term ADT tissue as well as CRPC tissue (90.0%, *p<0.05) compared to untreated primary PCa (60.7%). The frequency of Stat5 expression in different human PCa states is illustrated in figure 1B (right).
Expression of Stat5 protein and mRNA levels in prostate cancer cell lines
We next assessed expression of Stat5 at the protein and mRNA levels. Using an antibody detecting both isoforms a and b, western blot analysis showed that Stat5 is expressed in LNCaP, C4-2 and DU145 cells. Stat5 protein expression was higher in the AR-positive AI cell line C4-2 and the AR-negative AI cell line DU 145 compared to the AR-positive, androgen sensitive cell line LNCaP (Fig. 1C) .
Using qRT-PCR, we observed that the mRNA expression level of Stat5b was significantly higher compared to Stat5a (***, p<0.001) in LNCaP, C4-2 and DU 145 cells (Fig. 1D) . The ratio between both isoforms was on average 3.0, 5. Sequence-specific, dose-dependent knockdown of Stat5 by ASO in PCa cell lines in vitro ISIS 424751 potently suppressed Stat5 expression in a dose-dependent and sequence-specific fashion at both protein and mRNA levels. In LNCaP, C4-2, and DU 145 cells, Stat5 protein was potently suppressed at 30nM. ISIS 424751 had no effect on the expression of Stat3, confirming its specificity to Stat5 (Fig. 2A) . Stat5b mRNA levels were significantly reduced in LNCaP, C4-2 and DU145 cells in a dose dependent manner up to 75%, 85% and 93%, respectively (***, p<0.001). For Stat5a, maximum mRNA knockdown of 59%, 47% and 59% was reached at 30nM in LNCaP, C4-2 (*, p<0.05) and DU145 cells (**, p<0.01) (Fig. 2B ).
Stat5 knockdown inhibits PCa cell growth in vitro
LNCaP, C4-2 and DU 145 cells were treated for 2 days with 1 to 50nM ISIS 424751 or ScrB and growth rates were examined. Figure 2C shows a significant reduction of cell growth in all three cell lines 3 days after treatment with ISIS 424751 alone compared with ScrB in a dosedependent manner (***, p<0.001). IC50 was reached at 30nM, 20nM and 30nM for LNCaP, C4-2 and DU145 cells. In PC3 cells used as a Stat5 negative control, ISIS 424751 decreased cell growth by 8.0 % at 30nM (data not shown). ISIS 424751 significantly decreased cell growth rates at 30nM in LNCaP cells compared to control. In C4-2 and DU 145 cells, time-dependent cell growth was already significantly affected at 10nM ( Figure 2D ).
Stat5 ASO treatment induces apoptosis PCa cells in vitro
To assess effects of Stat5 knockdown using ISIS 424751 on cell apoptosis, we evaluated its effect on cell cycle population using flow cytometry, caspase-3 activity and cleaved poly (ADPribose) polymerase (PARP). As shown in Figure 3A , the fraction of cells undergoing apoptosis (sub G0/G1) was significantly increased in a dose dependent manner for Stat5-ASO treated LNCaP, C4-2 and DU 145 cells compared to ScrB (9.5% vs. 4 
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< 0.01).
Caspase-3 activity was significantly increased in LNCaP, C4-2 and DU 145 cells treated with ISIS 424751 compared to ScrB starting at 30nM (*, p<0.05), 50nM (**, p<0.01) and 30nM (**, p<0.01), respectively (Fig. 3B) . Furthermore, cells treated with ISIS 424751 expressed higher amounts of cleaved PARP compared with ScrB. Moreover, we found that ISIS 424751 induces a decrease of Cyclin D1 and Bcl-xL expression in a dose-dependent manner in all 3 cell lines (Fig.   3C ).
Effect of Stat5 on AR transcriptional activity and nuclear translocation
To determine effects of Stat5 on androgen-induced AR-mediated gene activation, LNCaP and C4-2 cells were treated with ISIS 424751 or ScrB and evaluated for changes in R1881-stimulated PSA transactivation (Fig. 4A) . Stat5 knockdown significantly abrogated the transactivation of the androgen-regulated PSA reporter in a dose dependent manner in LNCaP (*, p<0.05 at 10nM; *, p<0.05 at 30nM; ***, p<0.001 at 50nM) and C4-2 cells (*, p<0.05 at 10nM; *, p<0.05 at 30nM; ***, p<0.001 at 50nM). AR localization using immunofluorescence after ISIS 424751 +/-R1881 in LNCaP and C4-2 cells demonstrated that Stat5 knockdown abrogates R1881-induced AR nuclear translocation compared to ScrB treated cells. Interestingly, AR staining was lower after Stat5 knockdown (Fig 4B) .
Stat5 knockdown decreases AR stability and induces its degradation via the proteasome
To further explore the role of Stat5 knockdown on AR expression, we evaluated changes in AR proteins levels after treatment with ISIS 424751 in AR-positive LNCaP and C4-2 cells. ISIS 424751 decreased AR and PSA protein levels in a dose dependent manner (Fig. 5A) . In LNCaP cells, AR as well as PSA was potently suppressed at 30nM, while in C4-2 cells knockdown for both proteins was reached at 50nM. AR-mRNA expression levels were not affected by Stat5-ASO treatment (Fig. 5B) 
evaluated using CHX, which inhibits protein synthesis by blocking ribosomes ( Figure 5C ). AR protein levels decreased with rapid degradation after Stat5 knockdown by ISIS 424751 compared to ScrB treatment in LNCaP and C4-2 cells.
AR degradation after Stat5-knockdown occurs via the proteasome pathway because treatment with the proteasome inhibitor MG-132 suppressed Stat5 knockdown-induced AR protein degradation in LNCaP cells (Fig. 5D) . In summary, these findings indicate that Stat5 knockdown induces AR protein degradation via the proteasome pathway. Serum PSA levels were reduced in the ISIS 424751 treated group compared to control. To quantify treatment effects on target protein reduction, protein expression levels for Stat5, AR and Cyclin D1 in tumor tissue (3 animals per group) were evaluated using western analysis (Fig. 6C) .
Total Stat5 and AR protein expression were significantly downregulated in ISIS 424751 treated mice by 67.6% and 90.1%, respectively, compared to control mice (*, p<0.05), while Cyclin D1 showed no significant difference between both groups. This result supports the notion that androgen deprivation leads to an upgregulation of the JAK2-Stat5 signaling cascade, which allows cancer cells to survive in low-androgen environments.
Following androgen ablation, prolactin and other mitogens may function as promoters of the JAK2-Stat5-signaling cascade (22, (33) (34) (35) . Based on these findings we selected castraterecurrent LNCaP xenografts to model the human situation of CRPC (36).
The individual roles of the Stat5a and Stat5b isoforms remain unclear. Several studies suggest that both isoforms are expressed at different levels in different human PCa cell lines (21, 24) . Data on the ratio of isoform expression-levels in human PCa have not been previously reported. In the current study, we demonstrate that mRNA expression of Stat5b was 3.0 to 5.4 fold higher than isoform Stat5a in several PCa cell lines. These findings support the assumption of several studies that Stat5b plays a greater role in cancer cell growth and cancer progression than does Stat5a (21, 37).
While targeting Stat5 in vitro using ASO or siRNA has been reported previously (20, 23) , no study so far has reported on pharmacologic Stat5 inhibition in vivo. In this study, we used a second generation ASO incorporating a 2'-O-methoxyethyl gapmer modified backbone, which enables favorable physicochemical, biochemical, and pharmacokinetic properties in vivo (38). Our data shows that ISIS 424751 suppresses Stat5 expression at protein and mRNA levels in LNCaP, C4-2 and DU145 cells (Fig.2A,B) . Expression of other members of Stat-family such as Stat3 was not affected. The downregulation achieved with ISIS 424751 was observed on Stat5 dependent genes such as Cyclin D1 and Bcl-xL, as shown by western blot (Fig. 3C) . (28) and results from persisting low levels of intracrine testosterone production (29) . Supported by the finding that the frequency of Stat5 expression is increased in different stages of hormonal treated PCa (Fig. 1A,   B ), Stat5 may act as a co-activator of AR in androgen deprived PCa.
We found that Stat5 knockdown leads to a decrease of AR protein levels and stability without affecting AR mRNA-levels (Fig 5A-C) . Furthermore, treatment with the proteasome inhibitor MG-132 suppressed Stat5 knockdown-induced AR degradation (Fig. 5D) . Taken together, these findings indicate that Stat5 knockdown induces AR degradation via a proteasome-mediated pathway.
We also investigated the effects of Stat5 knockdown on AR dependent genes such as PSA.
Targeting Stat5 with ISIS 424751 abrogated R1881 induced AR nuclear translocation and transcription activity (Fig. 3) . These results are supported by Tan et al (26) Stat 5b Stat 5a 
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